Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.
To precisely send a drug to its intended target in the body requires two things:
To treat diabetes directly, rather than manage its symptoms, doctors need a way to get drugs to cells that produce insulin. The key, Stanford researchers report, may be those cells’ affinity for zinc.
An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported.